Drug Profile
Research programme- cancer therapeutics - Proteros Biostructures/ Merck
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Proteros Biostructures
- Developer Merck Sharp & Dohme; Proteros Biostructures
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in Germany
- 22 Nov 2016 Proteros Biostructures and Merck Sharp & Dohme enter into a second collaboration for epigenetic drug discovery for Cancer
- 30 Dec 2015 Proteros Biostructures and Merck Sharp & Dohme enter into a collaboration for epigenetic drug discovery for Cancer